[
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "ConfirmAgeEntered",
    "args": []
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "ConfirmWeightEntered",
    "args": []
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get immunosuppression state"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get pseudomonas risk"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get penicillin tolerance"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get recent broad spectrum antibiotics history"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get fungal infection risk"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get rickettsial risk"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get ESBL prevalence"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get Cefepime/Ceftadizime/Carbapenam resistance"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get Staphylococcus prevalence"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Instruct",
    "args": ["get HSV risk"]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "RecommendDrug",
    "args": [
        "Children > 28 days who are immunosuppressed or at risk for infection with Pseudomonas species",
        "OSF Antibiotics Set",
        "drug combination",
        "vancomycin (15 mg/kg, maximum 1 to 2 g, for the initial dose)"
    ]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Recommend",
    "args": [
        "consider additional antibiotics",
        "PLUS cefepime (50 mg/kg, maximum 2 g, for the initial dose) OR ceftadizime (50 mg/kg, maximium 2 g, for the initial dose) OR carbapenam (eg, imipenem, meroenem) in settings where bacterial organisms with extended-specturm beta-lactamase (ESBL) resistance are prevalent or for patients who have been recently (within two weeks) treated with broad-spectrum antibiotics (eg, third-generation celphalosporin, or fluoroquinolone)"
    ]
  },
  {
    "id": "tabletApp",
    "interface": "TabletApp",
    "name": "Recommend",
    "args": [
        "consider additional antibiotics",
        "ADD an Aminoglycoside (e.g. gentamicin, amikacin) for cefepime/ceftadizime/carbapenam resistance"
    ]
  }
]

